Pfizer Inc. “Fraudulent Marketing”: “Largest Health Care Fraud Settlement in Its History” (2009). US Department of Justice

Pfizer to Pay $2.3 Billion for Fraudulent Marketing

All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).

***

First posted on Global Research on July 19, 2021

.

Introductory Note

This text originally published by the US Department of Justice in September 2009 is of utmost relevance in assessing the current actions of Big Pharma in promoting pharmaceutical products which are detrimental to people’s health.

Pfizer is currently involved in marketing its experimental mRNA vaccine. The FDA in an ambiguous statement has provided an Emergency Use Authorization (EUA) to the Pfizer-BioNTech COVID-19 Vaccine, while underscoring that the vaccine is “an unapproved product”.  There is something “contradictory” in the FDA statement. The experimental Pfizer mRNA vaccine is “unapproved” by the FDA, yet it is “permitted”. 

In recent developments, a Confidential Pfizer Report released as part of a Freedom of Information (FOI) procedure provides data on deaths and adverse events recorded by Pfizer from the outset of the vaccine project in December 2020 to the end of February 2021, namely a very short period (at most two and a half months).

The Pfizer BioNTech vaccine was launched in the US on the 14th of December after the granting of Emergency Use Authorization on December 11, 2020. 

In a twisted irony, the data revealed in this “insider report” refutes the official vaccine narrative peddled by the governments and the WHO. It also confirms the analysis of numerous medical doctors and scientists who have revealed the devastating consequences of the mRNA “vaccine”. 

What is contained in  Pfizer’s “confidential” report is detailed evidence on the impacts of the “vaccine” on mortality and morbidity. This data which emanates from the “Horse’s Mouth” can now be used to confront as well formulate legal procedures against Big Pharma, the governments, the WHO and the media.

These revelations are beyond “fraudulent marketing”:  they point to crimes against humanity.

For further details see:

Bombshell Document Dump on Pfizer Vaccine Data

By Global Research, December 23, 2021

Global Research, December 27, 2021

***

Below the text of the US Department of Justice 2009 Settlement with Pfizer, Inc.

Of relevance, the DoJ judgment required that Pfizer Inc. enter into a so-called “corporate integrity agreement” with the Office of the Inspector General of the DHHS.

The integrity agreement included procedures to ensure that Pfizer’s “conduct” would not happen again.

 

 

American pharmaceutical giant Pfizer Inc. and its subsidiary Pharmacia & Upjohn Company Inc. (hereinafter together “Pfizer”) have agreed to pay $2.3 billion, the largest health care fraud settlement in the history of the Department of Justice, to resolve criminal and civil liability arising from the illegal promotion of certain pharmaceutical products, the Justice Department announced today.

Pharmacia & Upjohn Company has agreed to plead guilty to a felony violation of the Food, Drug and Cosmetic Act for misbranding Bextra with the intent to defraud or mislead. Bextra is an anti-inflammatory drug that Pfizer pulled from the market in 2005. Under the provisions of the Food, Drug and Cosmetic Act, a company must specify the intended uses of a product in its new drug application to FDA. Once approved, the drug may not be marketed or promoted for so-called “off-label” uses – i.e., any use not specified in an application and approved by FDA. Pfizer promoted the sale of Bextra for several uses and dosages that the FDA specifically declined to approve due to safety concerns. The company will pay a criminal fine of $1.195 billion, the largest criminal fine ever imposed in the United States for any matter. Pharmacia & Upjohn will also forfeit $105 million, for a total criminal resolution of $1.3 billion.

In addition, Pfizer has agreed to pay $1 billion to resolve allegations under the civil False Claims Act that the company illegally promoted four drugs – Bextra; Geodon, an anti-psychotic drug; Zyvox, an antibiotic; and Lyrica, an anti-epileptic drug – and caused false claims to be submitted to government health care programs for uses that were not medically accepted indications and therefore not covered by those programs. The civil settlement also resolves allegations that Pfizer paid kickbacks to health care providers to induce them to prescribe these, as well as other, drugs. The federal share of the civil settlement is $668,514,830 and the state Medicaid share of the civil settlement is $331,485,170. This is the largest civil fraud settlement in history against a pharmaceutical company.

As part of the settlement, Pfizer also has agreed to enter into an expansive corporate integrity agreement with the Office of Inspector General of the Department of Health and Human Services. That agreement provides for procedures and reviews to be put in place to avoid and promptly detect conduct similar to that which gave rise to this matter. (emphasis added)

To read the entire DoJ document, click here

 

*

Note to readers: please click the share buttons above or below. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.


Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: [email protected]

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: [email protected]